BioSight
Companies
Apellis Pharmaceuticals, Inc. logo

APLS

NASDAQWALTHAM, MA
Apellis Pharmaceuticals, Inc.

Apellis develops drugs using complement inhibition technology to treat rare and serious diseases across multiple therapeutic areas. The company has two marketed products—EMPAVELI and SYFOVRE—that have received regulatory approval and are in commercial stage. Apellis is also conducting ongoing clinical trials for additional product candidates aimed at expanding its pipeline and treatment indications.

Price history not yet available for APLS.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar